Discovery To Hope: Advancing Vector-Based Gene Therapies For Parkinson’s Disease

Gain an inside look at:

The science and technology behind the development and testing of viral vectors
The advantages and efficacy of the baculovirus expression vector system (BEVS) in gene therapy
Transitioning from small-scale proof of concept to larger-scale GMP viral vector manufacturing
How partnering with large and experienced CDMOs can help advance treatment development

Your company email address

Please select your industry: (max 1)
What gene modification modality are you working with? Check all that apply. (max 1)
What is your current phase of gene therapy development? (max 1)
Are you planning to outsource any phase of your viral vector therapy development/manufacturing? (max 1)

By you requesting this resource, you agree to our terms of use. All data is protected by our Privacy Notice. You can change your contact preferences here. If you have any further questions please get in contact.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
Thermo Fisher Scientific (including its affiliates) may contact me about events, products, services and promotions which Thermo Fisher believes may be of interest to me via email and will process my Personal Information according to its privacy policy. I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com. I acknowledge Thermo Fisher Scientific (including its affiliates) will process my Personal Information according to its Privacy Policy, which includes information about my rights

Explore similar content